Company Analysis Amicus Therapeutics, Inc.
1. Summary
Advantages
- Price (6.17 $) is less than fair price (9.68 $)
- The company's current efficiency (ROE=-31.68%) is higher than the sector average (ROE=-83.32%)
Disadvantages
- Dividends (0%) are below the sector average (1.28%).
- The stock's return over the last year (-47.04%) is lower than the sector average (-4.96%).
- Current debt level 56.51% has increased over 5 years from 24.72%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Amicus Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0.2% | 0.6% | -0.6% |
| 90 days | -10.4% | -3.9% | 5.8% |
| 1 year | -47% | -5% | 9.1% |
FOLD vs Sector: Amicus Therapeutics, Inc. has significantly underperformed the "Healthcare" sector by -42.08% over the past year.
FOLD vs Market: Amicus Therapeutics, Inc. has significantly underperformed the market by -56.15% over the past year.
Stable price: FOLD is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: FOLD with weekly volatility of -0.9046% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (6.17 $) is lower than the fair price (9.68 $).
Price significantly below the fair price: The current price (6.17 $) is 56.9% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (52.65).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (61.83).
4.3. P/BV
P/BV vs Sector: The company's P/BV (14.76) is higher than that of the sector as a whole (10.86).
P/BV vs Market: The company's P/BV (14.76) is lower than that of the market as a whole (20.82).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (5.42) is higher than that of the sector as a whole (4.03).
P/S vs Market: The company's P/S indicator (5.42) is lower than that of the market as a whole (16).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (105.28) is higher than that of the sector as a whole (16.78).
EV/Ebitda vs Market: The company's EV/Ebitda (105.28) is higher than that of the market as a whole (27.04).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -15.95% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-15.95%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-8.87%).
5.4. ROE
ROE vs Sector: The company's ROE (-31.68%) is higher than that of the sector as a whole (-83.32%).
ROE vs Market: The company's ROE (-31.68%) is lower than that of the market as a whole (43%).
5.5. ROA
ROA vs Sector: The company's ROA (-7.18%) is lower than that of the sector as a whole (6.43%).
ROA vs Market: The company's ROA (-7.18%) is lower than that of the market as a whole (23.28%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.2%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.28%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
